$ABT · Abbott Laboratories
Abbott Laboratories filed a Form 4 with the SEC on October 2, 2026, reporting a change in beneficial ownership by Patricia Paola Gonzalez, a director of the company. The filing states that on September 30, 2026, she acquired 333 stock equivalent units at a price of $98.83 each. After the transaction, she beneficially owned 6,331 stock equivalent units directly.
According to the filing, the stock equivalent units represent director fees credited to a grantor trust established by the director. These units earn the same return as if the fees were invested in Abbott common shares and are generally paid in cash at age 65 or upon retirement from the board. The balance also includes stock equivalent units acquired through a dividend reinvestment feature.